≤/>90% FVC PREDICTED

A post hoc subgroup analysis in patients with ≤90% and >90% FVC predicted at baseline1

Objective and methods

  • A post hoc subgroup analysis of pooled data from the INPULSIS® trials was used to evaluate the treatment effect (annual rate of FVC decline) of OFEV (nintedanib) in patients with FVC ≤90% predicted compared to those with FVC >90% predicted at baseline

Proportion of patients with ≤90% and >90% FVC predicted at baseline in the pooled INPULSIS® population (OFEV and placebo arms)

Proportion of patients with FVC predicted at baseline in the pool INPULSIS® population Proportion of patients with FVC predicted at baseline in the pool INPULSIS® population

Annual rate of FVC decline results from a post hoc subgroup analysis of the pooled INPULSIS® trials

Annual rate of FVC decline results from a post hoc subgroup analysis of the pooled INPULSIS® trials. Annual rate of FVC decline results from a post hoc subgroup analysis of the pooled INPULSIS® trials.
  • Placebo-treated patients with a baseline FVC >90% predicted declined at a similar rate to patients with a baseline FVC ≤90% predicted over 52 weeks (-225 mL/year vs -224 mL/year, respectively)
  • The treatment effect was not different between patients with FVC ≤90% predicted and those with FVC >90% predicted, as indicated by the nonsignificant treatment-by-subgroup interaction (P=.530)
  • Both subgroups had a similar adverse events profile

Limitations

  • This is a post hoc subgroup analysis. Results are exploratory in nature and cannot be used to demonstrate statistical differences between treatment groups2

In a subgroup analysis, OFEV reduced the annual rate of FVC decline in patients with FVC ≤90% and >90% predicted at baseline1

≤/>70% FVC PREDICTED

A prespecified subgroup analysis in patients with ≤70% and >70% FVC predicted at baseline2

Objective and methods

  • A prespecified subgroup analysis of pooled data from the INPULSIS® trials was used to evaluate the treatment effect (annual rate of FVC decline) of OFEV in patients with FVC ≤70% predicted compared to those with FVC >70% predicted at baseline

Proportion of patients with ≤70% and >70% FVC predicted at baseline in the pooled INPULSIS® population (OFEV and placebo arms)

OFEV® INPULSIS® clinical trials FVC predicted at 70 percent OFEV® INPULSIS® clinical trials FVC predicted at 70 percent

Annual rate of FVC decline results from a prespecified subgroup analysis of the pooled INPULSIS® trials2

OFEV® FVC decline 70 percent baseline OFEV® FVC decline 70 percent baseline
  • Placebo-treated patients with a baseline FVC >70% predicted declined at a similar rate to patients with a baseline FVC ≤70% predicted over 52 weeks (-220 mL/year vs -233 mL/year, respectively)
  • The treatment effect was not different between patients with FVC ≤70% predicted and those with FVC >70% predicted, as indicated by the nonsignificant treatment-by-subgroup interaction (P=.9505)

LIMITATIONS

  • This is a prespecified subgroup analysis. Results are exploratory in nature and cannot be used to demonstrate statistical differences between treatment groups2

In a subgroup analysis, OFEV reduced the annual rate of FVC decline in patients with FVC ≤70% and >70% predicted at baseline2

WITH or WITHOUT
CONCOMITANT EMPHYSEMA

A post hoc subgroup analysis in patients with and without concomitant emphysema2

Objective and methods2,3

  • A post hoc subgroup analysis of pooled data from the INPULSIS® trials to evaluate the treatment effect (annual rate of FVC decline) in patients with or without emphysema on HRCT at baseline. Concomitant centrilobular emphysema was diagnosed on HRCT based on qualitative assessment

Proportion of patients with and without concomitant emphysema in the pooled INPULSIS® population (OFEV and placebo arms)2

INPULSIS® clinical trials FVC predicted emphysema INPULSIS® clinical trials FVC predicted emphysema

Annual rate of FVC decline results from a post hoc subgroup analysis of the pooled INPULSIS® trials2

OFEV® FVC decline emphysema HRCT baseline OFEV® FVC decline emphysema HRCT baseline
  • Placebo-treated patients with concomitant emphysema declined at a similar rate to patients without emphysema over 52 weeks (-207 mL/year vs -234 mL/year, respectively)
  • The treatment effect of OFEV on the annual rate of FVC decline was not different between patients with or without emphysema on HRCT at baseline, as indicated by the nonsignificant treatment-by-subgroup interaction (P=.5199)
  • Both subgroups had a similar adverse events profile

LIMITATIONS

  • This is a post hoc subgroup analysis. Results are exploratory in nature and cannot be used to demonstrate statistical differences between treatment groups2

In a subgroup analysis, OFEV reduced the annual rate of FVC decline independent of the presence of emphysema at baseline2

CI, confidence interval; FVC, forced vital capacity; HRCT, high-resolution computed tomography.

IMPORTANT SAFETY
INFORMATION AND INDICATION

WARNINGS AND PRECAUTIONS

Hepatic Impairment

  • OFEV (nintedanib) is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment. Patients with mild hepatic impairment (Child Pugh A) can be treated with a reduced dosage (100 mg twice daily). Consider treatment interruption or discontinuation for management of adverse reactions.

Elevated Liver Enzymes and Drug-Induced Liver Injury

  • Cases of drug-induced liver injury (DILI) have been observed with OFEV treatment. In the post-marketing period, non-serious and serious cases of DILI, including severe liver injury with fatal outcome, have been reported. The majority of hepatic events occur within the first three months of treatment. OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, and GGT) and bilirubin. Liver enzyme and bilirubin increases were reversible with dose modification or interruption in the majority of cases. The majority (94%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN. The majority (95%) of patients with bilirubin elevations had elevations less than 2 times ULN.
  • Patients with a low body weight (less than 65 kg), Asian, and female patients may have a higher risk of elevations in liver enzymes. Nintedanib exposure increased with patient age, which may result in increased liver enzymes.
  • Conduct liver function tests prior to initiation of treatment, at regular intervals during the first three months of treatment, and periodically thereafter or as clinically indicated. Measure liver function tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. Dosage modifications, interruption, or discontinuation may be necessary for liver enzyme elevations.

Gastrointestinal Disorders

Diarrhea

  • Diarrhea was the most frequent gastrointestinal event reported in 62% versus 18% of patients treated with OFEV and placebo, respectively. Events were primarily mild to moderate intensity and occurred within the first 3 months. Diarrhea led to permanent dose reduction in 11% and discontinuation in 5% of OFEV patients versus 0 and less than 1% in placebo patients, respectively.
  • Dosage modifications or treatment interruptions may be necessary in patients with diarrhea. Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider treatment interruption if diarrhea continues. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists, discontinue treatment.

Nausea and Vomiting

  • Nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively. Events were primarily of mild to moderate intensity. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.
  • If nausea or vomiting persists despite appropriate supportive care including anti-emetic therapy, consider dose reduction or treatment interruption. OFEV treatment may be resumed at full dosage or at reduced dosage, which subsequently may be increased to full dosage. If severe nausea or vomiting does not resolve, discontinue treatment.

Embryofetal Toxicity: OFEV can cause fetal harm when administered to a pregnant woman and patients should be advised of the potential risk to a fetus. Women should be advised to avoid becoming pregnant while receiving OFEV and to use effective contraception during treatment and at least 3 months after the last dose of OFEV. Verify pregnancy status prior to starting OFEV.

Arterial Thromboembolic Events: Arterial thromboembolic events were reported in 2.5% of OFEV and 0.8% of placebo patients, respectively. Myocardial infarction was the most common arterial thromboembolic event, occurring in 1.5% of OFEV and 0.4% of placebo patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.

Risk of Bleeding: OFEV may increase the risk of bleeding. Bleeding events were reported in 10% of OFEV versus 7% of placebo patients. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk. In the post-marketing period, non-serious and serious bleeding events, some of which were fatal, have been observed.

Gastrointestinal Perforation: OFEV may increase the risk of gastrointestinal perforation. Gastrointestinal perforation was reported in 0.3% of OFEV versus in 0% placebo patients. In the post-marketing period, cases of gastrointestinal perforations have been reported, some of which were fatal. Use caution when treating patients who have had recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

ADVERSE REACTIONS

  • Adverse reactions reported in greater than or equal to 5% of OFEV patients included diarrhea, nausea, abdominal pain, liver enzyme elevation, vomiting, decreased appetite, weight decreased, headache, and hypertension.
  • The most frequent serious adverse reactions reported in OFEV patients were bronchitis and myocardial infarction. The most common adverse events leading to death in OFEV patients versus placebo were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). In the predefined category of major adverse cardiovascular events (MACE) including MI, fatal events were reported in 0.6% of OFEV versus 1.8% in placebo patients.

DRUG INTERACTIONS

  • P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers: Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of potent P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John’s wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib.
  • Anticoagulants: Nintedanib may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary.

USE IN SPECIFIC POPULATIONS

  • Nursing Mothers: Because of the potential for serious adverse reactions in nursing infants from OFEV, advise women that breastfeeding is not recommended during treatment.
  • Reproductive Potential: OFEV may reduce fertility in females of reproductive potential.
  • Smokers: Smoking was associated with decreased exposure to OFEV, which may affect the efficacy of OFEV. Encourage patients to stop smoking prior to and during treatment.
CL-OF-100007 01.29.18

Indication

OFEV (nintedanib) is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Click here for full Prescribing Information, including Patient Information.

References:

  1. Kolb M et al. Thorax. 2017;72(4):340-346.
  2. Data on file. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.
  3. Richeldi L et al; for the INPULSIS Trial Investigators. N Engl J Med. 2014;370(22):2071-2082.

IMPORTANT SAFETY
INFORMATION AND INDICATION

WARNINGS AND PRECAUTIONS

Hepatic Impairment

  • OFEV (nintedanib) is not recommended in patients with moderate (Child Pugh B) or severe (Child Pugh C) hepatic impairment. Patients with mild hepatic impairment (Child Pugh A) can be treated with a reduced dosage (100 mg twice daily). Consider treatment interruption or discontinuation for management of adverse reactions.

Elevated Liver Enzymes and Drug-Induced Liver Injury

  • Cases of drug-induced liver injury (DILI) have been observed with OFEV treatment. In the post-marketing period, non-serious and serious cases of DILI, including severe liver injury with fatal outcome, have been reported. The majority of hepatic events occur within the first three months of treatment. OFEV was associated with elevations of liver enzymes (ALT, AST, ALKP, and GGT) and bilirubin. Liver enzyme and bilirubin increases were reversible with dose modification or interruption in the majority of cases. The majority (94%) of patients with ALT and/or AST elevations had elevations less than 5 times ULN. The majority (95%) of patients with bilirubin elevations had elevations less than 2 times ULN.
  • Patients with a low body weight (less than 65 kg), Asian, and female patients may have a higher risk of elevations in liver enzymes. Nintedanib exposure increased with patient age, which may result in increased liver enzymes.
  • Conduct liver function tests prior to initiation of treatment, at regular intervals during the first three months of treatment, and periodically thereafter or as clinically indicated. Measure liver function tests promptly in patients who report symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice. Dosage modifications, interruption, or discontinuation may be necessary for liver enzyme elevations.

Gastrointestinal Disorders

Diarrhea

  • Diarrhea was the most frequent gastrointestinal event reported in 62% versus 18% of patients treated with OFEV and placebo, respectively. Events were primarily mild to moderate intensity and occurred within the first 3 months. Diarrhea led to permanent dose reduction in 11% and discontinuation in 5% of OFEV patients versus 0 and less than 1% in placebo patients, respectively.
  • Dosage modifications or treatment interruptions may be necessary in patients with diarrhea. Treat diarrhea at first signs with adequate hydration and antidiarrheal medication (e.g., loperamide), and consider treatment interruption if diarrhea continues. OFEV treatment may be resumed at the full dosage (150 mg twice daily), or at the reduced dosage (100 mg twice daily), which subsequently may be increased to the full dosage. If severe diarrhea persists, discontinue treatment.

Nausea and Vomiting

  • Nausea was reported in 24% versus 7% and vomiting was reported in 12% versus 3% of patients treated with OFEV and placebo, respectively. Events were primarily of mild to moderate intensity. Nausea and vomiting led to discontinuation of OFEV in 2% and 1% of patients, respectively.
  • If nausea or vomiting persists despite appropriate supportive care including anti-emetic therapy, consider dose reduction or treatment interruption. OFEV treatment may be resumed at full dosage or at reduced dosage, which subsequently may be increased to full dosage. If severe nausea or vomiting does not resolve, discontinue treatment.

Embryofetal Toxicity: OFEV can cause fetal harm when administered to a pregnant woman and patients should be advised of the potential risk to a fetus. Women should be advised to avoid becoming pregnant while receiving OFEV and to use effective contraception during treatment and at least 3 months after the last dose of OFEV. Verify pregnancy status prior to starting OFEV.

Arterial Thromboembolic Events: Arterial thromboembolic events were reported in 2.5% of OFEV and 0.8% of placebo patients, respectively. Myocardial infarction was the most common arterial thromboembolic event, occurring in 1.5% of OFEV and 0.4% of placebo patients. Use caution when treating patients at higher cardiovascular risk including known coronary artery disease. Consider treatment interruption in patients who develop signs or symptoms of acute myocardial ischemia.

Risk of Bleeding: OFEV may increase the risk of bleeding. Bleeding events were reported in 10% of OFEV versus 7% of placebo patients. Use OFEV in patients with known risk of bleeding only if the anticipated benefit outweighs the potential risk. In the post-marketing period, non-serious and serious bleeding events, some of which were fatal, have been observed.

Gastrointestinal Perforation: OFEV may increase the risk of gastrointestinal perforation. Gastrointestinal perforation was reported in 0.3% of OFEV versus in 0% placebo patients. In the post-marketing period, cases of gastrointestinal perforations have been reported, some of which were fatal. Use caution when treating patients who have had recent abdominal surgery, previous history of diverticular disease or receiving concomitant corticosteroids or NSAIDs. Discontinue therapy with OFEV in patients who develop gastrointestinal perforation. Only use OFEV in patients with known risk of gastrointestinal perforation if the anticipated benefit outweighs the potential risk.

ADVERSE REACTIONS

  • Adverse reactions reported in greater than or equal to 5% of OFEV patients included diarrhea, nausea, abdominal pain, liver enzyme elevation, vomiting, decreased appetite, weight decreased, headache, and hypertension.
  • The most frequent serious adverse reactions reported in OFEV patients were bronchitis and myocardial infarction. The most common adverse events leading to death in OFEV patients versus placebo were pneumonia (0.7% vs. 0.6%), lung neoplasm malignant (0.3% vs. 0%), and myocardial infarction (0.3% vs. 0.2%). In the predefined category of major adverse cardiovascular events (MACE) including MI, fatal events were reported in 0.6% of OFEV versus 1.8% in placebo patients.

DRUG INTERACTIONS

  • P-glycoprotein (P-gp) and CYP3A4 Inhibitors and Inducers: Coadministration with oral doses of a P-gp and CYP3A4 inhibitor, ketoconazole, increased exposure to nintedanib by 60%. Concomitant use of potent P-gp and CYP3A4 inhibitors (e.g., erythromycin) with OFEV may increase exposure to nintedanib. In such cases, patients should be monitored closely for tolerability of OFEV. Management of adverse reactions may require interruption, dose reduction, or discontinuation of therapy with OFEV. Coadministration with oral doses of a P-gp and CYP3A4 inducer, rifampicin, decreased exposure to nintedanib by 50%. Concomitant use of P-gp and CYP3A4 inducers (e.g., carbamazepine, phenytoin, and St. John’s wort) with OFEV should be avoided as these drugs may decrease exposure to nintedanib.
  • Anticoagulants: Nintedanib may increase the risk of bleeding. Monitor patients on full anticoagulation therapy closely for bleeding and adjust anticoagulation treatment as necessary.

USE IN SPECIFIC POPULATIONS

  • Nursing Mothers: Because of the potential for serious adverse reactions in nursing infants from OFEV, advise women that breastfeeding is not recommended during treatment.
  • Reproductive Potential: OFEV may reduce fertility in females of reproductive potential.
  • Smokers: Smoking was associated with decreased exposure to OFEV, which may affect the efficacy of OFEV. Encourage patients to stop smoking prior to and during treatment.
CL-OF-100007 01.29.18

Indication

OFEV (nintedanib) is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

Click here for full Prescribing Information, including Patient Information.